Holen Sie sich die Stockscreener-App
1.726
1.53%
0.026
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer to Advance Cancer Therapy Pipeline 1 - Minichart
ALX Oncology names Jeff Knight as chief development officer By Investing.com - Investing.com South Africa
ALX Oncology Appoints Jeff Knight to Lead Development - TipRanks
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Bitget
Jeff Knight joins ALX Oncology (NASDAQ: ALXO) as development chief - Stock Titan
ALX brings in 30-year biotech veteran ahead of key cancer milestones - Stock Titan
Profit Recap: What are the risks of holding ALX Oncology Holdings Inc2026 Final Week & Trade Opportunity Analysis - baoquankhu1.vn
Retail Trends: Can ALX Oncology Holdings Inc reach all time highs this year2026 Market WrapUp & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Geopolitics Watch: Is ALX Oncology Holdings Inc attractive at current valuation2026 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Block Trades: Will ALX Oncology Holdings Inc benefit from government policyPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALXO Technical Analysis & Stock Price Forecast - Intellectia AI
Certain Common Stock of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Performance Based Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Recap Report: Is ALX Oncology Holdings Inc a stock for growth or value investors2026 Retail Activity & Free Reliable Trade Execution Plans - baoquankhu1.vn
ALX Oncology Holdings (ALXO) price target increased by 38.00% to 4.69 - MSN
RSI Check: Should I invest in ALX Oncology Holdings Inc before earningsWeekly Trade Report & Verified Short-Term Plans - baoquankhu1.vn
Risk Off: Can ALX Oncology Holdings Inc reach all time highs this year2026 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Buy Signal: What is ALX Oncology Holdings Incs book value per shareQuarterly Trade Summary & Weekly High Momentum Picks - baoquankhu1.vn
Investment Review: Is ALX Oncology Holdings Inc benefiting from interest rate changes2026 Trends & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock - MarketBeat
ALX Oncology (ALXO) CEO sells 12,311 shares to cover tax obligations - Stock Titan
ALX Oncology (ALXO) finance SVP sells 903 shares to cover tax bill - Stock Titan
Risk Recap: Is ALX Oncology Holdings Inc attractive at current valuation2026 Update & Capital Efficient Trading Techniques - baoquankhu1.vn
Earnings Recap: Will ALX Oncology Holdings Inc stock hit new highs in YEAR2026 Trade Ideas & Community Verified Watchlist Alerts - baoquankhu1.vn
Wells Fargo initiates coverage of ALX Oncology Holdings (ALXO) with overweight recommendation - MSN
ALXO: Wells Fargo Initiates Coverage with Overweight Rating | AL - GuruFocus
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO) - MarketBeat
Wells Fargo initiates ALX Oncology stock with overweight rating By Investing.com - Investing.com Canada
Wells Fargo Initiates ALX Oncology at Overweight With $5 Price Target - marketscreener.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
IBRX Stock Jumps on Progress in NK Cell Therapy Production - sharewise.com
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study - tradingview.com
RLMD stock surges 42% in a week: Here's what you should know - msn.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Finviz
ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart
ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat
ALXO: HC Wainwright Reiterates Buy Rating with Price Target at $4.00 | ALXO Stock News - GuruFocus
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study - Finviz
Aug Momentum: What is ALX Oncology Holdings Incs book value per share2026 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn
Alx Oncology Earnings Call Highlights Biomarker Momentum - TipRanks
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):